Medpace (MEDP) Stock Price, News & Analysis

Company Overview

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Key Stats

• Today's Range: $412.35 to $425.88
• 50-Day Range: $293.58 to $477.73
• 52-Week Range: $250.05 to $501.30
• Volume: 517,813 shs
• Average Volume: 739,468 shs
• Market Capitalization: $11.88 billion
• P/E Ratio: 31.46
• Dividend Yield: N/A
• Price Target: $406.60
• Consensus Rating: Reduce

Medpace Stock Analysis - MarketRank™

Medpace scored higher than 84% of companies evaluated by MarketBeat, and ranked 150th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Medpace has received a consensus rating of Reduce. The company's average rating score is 1.93, and is based on 2 buy ratings, 9 hold ratings, and 3 sell ratings.

Amount of Analyst Coverage

Medpace has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 11.15%

Earnings Growth

Earnings for Medpace are expected to grow by 11.15% in the coming year, from $12.29 to $13.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medpace is 31.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medpace is 31.46, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

Price to Earnings Growth Ratio

Medpace has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Medpace has a P/B Ratio of 68.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.51% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Medpace has recently decreased by 6.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medpace does not currently pay a dividend.

Dividend Growth

Medpace does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.62

Percentage of Shares Shorted

13.51% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Medpace has recently decreased by 6.42%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.83

News Sentiment

Medpace has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 43 news articles for Medpace this week, compared to 13 articles on an average week.

Search Interest

13 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,018,354.00 in company stock.

Percentage Held by Insiders

20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MEDP Stock Analysis - Frequently Asked Questions

How have MEDP shares performed this year?

Medpace's stock was trading at $332.23 on January 1st, 2025. Since then, MEDP shares have increased by 27.3% and is now trading at $423.09.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, July, 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year.
Read the conference call transcript.

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's top institutional investors include Bessemer Group Inc. (1.81%), TD Asset Management Inc (1.63%), Riverbridge Partners LLC (1.51%) and Boston Trust Walden Corp (0.54%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Jesse J Geiger, Stephen P Ewald, Kevin M Brady, Fred B Davenport Jr, Ashley M Keating and Robert O Kraft.
View institutional ownership trends.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/21/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 10/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:MEDP
• CIK: 1668397
• Web: www.medpace.com
• Phone: (513) 579-9911
• Fax: 513-579-0444
• Employees: 5,900
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medpace: $406.60
• High Price Target: $510.00
• Low Price Target: $305.00
• Potential Upside/Downside: -3.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $13.45
• Trailing P/E Ratio: 31.46
• Forward P/E Ratio: 34.43
• P/E Growth: 2.69
• Net Income: $404.39 million
• Net Margins: 18.74%
• Pretax Margin: 22.20%
• Return on Equity: 67.66%
• Return on Assets: 21.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.43

Sales & Book Value

• Annual Sales: $2.11 billion
• Price / Sales: 5.64
• Cash Flow: $13.82 per share
• Price / Cash Flow: 30.62
• Book Value: $6.14 per share
• Price / Book: 68.91

Miscellaneous

• Outstanding Shares: 28,090,000
• Free Float: 22,390,000
• Market Cap: $11.88 billion
• Optionable: Optionable
• Beta: 1.42